Scholarlink

<p>The potassium-competitive acid blockers (P-CABs) are a novel class of potent antisecretory drugs that unlike the proton pump inhibitors (PPIs) are not dependent on activated proton pumps, acting near maximally from the first dose, a pharmacokinetic advantage over PPIs. Tegoprazan, a novel P-CAB, offers potent and rapid acid suppression without delaying gastric emptying, distinguishing it from PPIs. This commentary contextualizes these results within the broader landscape of functional dyspepsia management, highlighting the potential benefits of tegoprazan in patients requiring antisecretory therapy, emphasizing the need for further research into its long-term impacts on motility, gut microbiota composition, and symptomatology. This analysis underscores how P-CABs may redefine antisecretory therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PPIs Have It: Does Tegoprazan Affect Gastric Emptying and Produce Dyspeptic Symptoms?

  • 期刊论文

  • 发表日期：

    2025年2月19日

查看全文
  • José María Remes-Troche

摘要

The potassium-competitive acid blockers (P-CABs) are a novel class of potent antisecretory drugs that unlike the proton pump inhibitors (PPIs) are not dependent on activated proton pumps, acting near maximally from the first dose, a pharmacokinetic advantage over PPIs. Tegoprazan, a novel P-CAB, offers potent and rapid acid suppression without delaying gastric emptying, distinguishing it from PPIs. This commentary contextualizes these results within the broader landscape of functional dyspepsia management, highlighting the potential benefits of tegoprazan in patients requiring antisecretory therapy, emphasizing the need for further research into its long-term impacts on motility, gut microbiota composition, and symptomatology. This analysis underscores how P-CABs may redefine antisecretory therapies.